Humacyte, Inc.
HUMA
$1.39
$0.010.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 289.94% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 289.94% | -- | -- | -- | -- |
| Cost of Revenue | 1.74% | -10.83% | -13.79% | -2.85% | 2.94% |
| Gross Profit | 0.07% | 13.13% | 15.57% | 3.82% | -2.29% |
| SG&A Expenses | 7.84% | 20.82% | 27.16% | 32.65% | 39.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.30% | -3.69% | -4.92% | 4.84% | 10.41% |
| Operating Income | -1.97% | 5.47% | 6.31% | -4.07% | -9.90% |
| Income Before Tax | -25.65% | 72.54% | 75.82% | 58.00% | 26.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.65% | 72.54% | 75.82% | 58.00% | 26.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.65% | 72.54% | 75.82% | 58.00% | 26.52% |
| EBIT | -1.97% | 5.47% | 6.31% | -4.07% | -9.90% |
| EBITDA | -2.04% | 5.98% | 6.89% | -4.29% | -10.91% |
| EPS Basic | 16.59% | 83.69% | 82.23% | 63.93% | 31.64% |
| Normalized Basic EPS | 34.80% | 49.18% | 37.99% | 25.49% | 17.76% |
| EPS Diluted | 17.00% | 83.74% | 82.29% | 64.05% | 31.19% |
| Normalized Diluted EPS | 34.79% | 49.20% | 38.00% | 25.51% | 17.77% |
| Average Basic Shares Outstanding | 40.50% | 33.39% | 27.04% | 22.75% | 18.73% |
| Average Diluted Shares Outstanding | 40.43% | 33.45% | 27.10% | 22.81% | 18.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |